Purple Biotech Identifies Potential New Serum Biomarker For Its Lead Oncology Therapeutic Candidate CM24: Associated With 79% Reduction In Risk Of Death
Purple Biotech Identifies Potential New Serum Biomarker For Its Lead Oncology Therapeutic Candidate CM24: Associated With 79% Reduction In Risk Of Death
REHOVOT, Israel, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that overcome tumor immune evasion and drug resistance, today announced it has identified serum CEACAM1 as an additional new potential blood biomarker that may help determine which metastatic pancreatic ductal adenocarcinoma (PDAC) patients are most likely to benefit from treatment with CM24. CM24 is a humanized monoclonal antibody that blocks CEACAM1 binding thereby inhibits its activity. CEACAM1 is overexpressed on certain tumor cells, immune cells, and neutrophils extracellular traps (NETs).Patients with serum CEACAM1 within a defined range prior to treatment demonstrated increased overall survival (OS) and progression free survival (PFS) when treated with CM24
治療前血清CEACAM1在確定範圍內的患者，接受CM24治療後表現出提高的總生存率（OS）和無進展生存率（PFS）
Definition of serum biomarkers for patient selection offers a substantial advantage in developing treatments for cancer
定義血清生物標誌物以供病人選擇，在癌症治療研發中具有重大優勢
CM24, a CEACAM1 inhibitor, is currently being evaluated in a Phase 2 randomized pancreatic cancer study, with topline results expected in Q4 of 2024
CM24是CEACAM1抑制劑，目前正在進行第2期隨機胰腺癌研究評估，預計於2024年第四季度發佈最終結果
REHOVOT, Israel, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that overcome tumor immune evasion and drug resistance, today announced it has identified serum CEACAM1 as an additional new potential blood biomarker that may help determine which metastatic pancreatic ductal adenocarcinoma (PDAC) patients are most likely to benefit from treatment with CM24. CM24 is a humanized monoclonal antibody that blocks CEACAM1 binding thereby inhibits its activity. CEACAM1 is overexpressed on certain tumor cells, immune cells, and neutrophils extracellular traps (NETs).
以色列雷霍沃特，2024年11月4日（環球新聞社）-- 紫生物技術有限公司（"紫生物技術"或"該公司"）（納斯達克/特拉維夫證券交易所：PPBT），一家開發首創類治療方法，用以克服腫瘤免疫逃逸和藥物抵抗的臨床階段公司，今日宣佈已確定血清CEACAM1作爲可能有助於判斷何種轉移性胰腺導管腺癌（PDAC）患者最可能受益於CM24治療的新潛在血液生物標誌物。CM24是一種人源化單克隆抗體，可阻止CEACAM1的結合，從而抑制其活性。CEACAM1在特定腫瘤細胞、免疫細胞和中性粒細胞外圍陷阱（NETs）上過表達。
